416 related articles for article (PubMed ID: 11774202)
21. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy.
Itamochi H; Kigawa J; Kanamori Y; Oishi T; Bartholomeusz C; Nahta R; Esteva FJ; Sneige N; Terakawa N; Ueno NT
Mol Cancer Ther; 2007 Jan; 6(1):227-35. PubMed ID: 17218636
[TBL] [Abstract][Full Text] [Related]
23. [Development of HER2-specific humanized antibody Herceptin (trastuzumab)].
Nihira S
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):504-14. PubMed ID: 14639005
[TBL] [Abstract][Full Text] [Related]
24. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.
Hortobagyi GN; Ueno NT; Xia W; Zhang S; Wolf JK; Putnam JB; Weiden PL; Willey JS; Carey M; Branham DL; Payne JY; Tucker SD; Bartholomeusz C; Kilbourn RG; De Jager RL; Sneige N; Katz RL; Anklesaria P; Ibrahim NK; Murray JL; Theriault RL; Valero V; Gershenson DM; Bevers MW; Huang L; Lopez-Berestein G; Hung MC
J Clin Oncol; 2001 Jul; 19(14):3422-33. PubMed ID: 11454891
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.
Kumar-Sinha C; Ignatoski KW; Lippman ME; Ethier SP; Chinnaiyan AM
Cancer Res; 2003 Jan; 63(1):132-9. PubMed ID: 12517789
[TBL] [Abstract][Full Text] [Related]
27. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
28. The role of overexpressed HER2 in transformation.
Neve RM; Lane HA; Hynes NE
Ann Oncol; 2001; 12 Suppl 1():S9-13. PubMed ID: 11521729
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
30. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
31. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
32. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
33. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
34. Strategies to target HER2/neu overexpression for cancer therapy.
Chen JS; Lan K; Hung MC
Drug Resist Updat; 2003 Jun; 6(3):129-36. PubMed ID: 12860460
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
36. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
37. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
38. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
40. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
